- Home
- SXTP vs VTAK Comparison
SXTP vs VTAK Comparison
Compare SXTP & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- VTAK
- Stock Information
- Founded
- SXTP 2010
- VTAK 2002
- Country
- SXTP United States
- VTAK United States
- Employees
- SXTP N/A
- VTAK N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- VTAK Medical/Dental Instruments
- Sector
- SXTP Health Care
- VTAK Health Care
- Exchange
- SXTP Nasdaq
- VTAK Nasdaq
- Market Cap
- SXTP 1.6M
- VTAK 1.4M
- IPO Year
- SXTP 2023
- VTAK 2018
- Fundamental
- Price
- SXTP $0.90
- VTAK $0.47
- Analyst Decision
- SXTP Hold
- VTAK
- Analyst Count
- SXTP 1
- VTAK 0
- Target Price
- SXTP N/A
- VTAK N/A
- AVG Volume (30 Days)
- SXTP 87.9K
- VTAK 1.4M
- Earning Date
- SXTP 11-26-2024
- VTAK 12-19-2024
- Dividend Yield
- SXTP N/A
- VTAK N/A
- EPS Growth
- SXTP N/A
- VTAK N/A
- EPS
- SXTP N/A
- VTAK N/A
- Revenue
- SXTP $462,612.00
- VTAK $399,000.00
- Revenue This Year
- SXTP $267.05
- VTAK $637.10
- Revenue Next Year
- SXTP $181.82
- VTAK $177.13
- P/E Ratio
- SXTP N/A
- VTAK N/A
- Revenue Growth
- SXTP 12.07
- VTAK 140.88
- 52 Week Low
- SXTP $0.70
- VTAK $0.31
- 52 Week High
- SXTP $18.36
- VTAK $4.10
- Technical
- Relative Strength Index (RSI)
- SXTP 47.11
- VTAK 44.39
- Support Level
- SXTP $0.87
- VTAK $0.45
- Resistance Level
- SXTP $1.14
- VTAK $0.62
- Average True Range (ATR)
- SXTP 0.12
- VTAK 0.07
- MACD
- SXTP 0.02
- VTAK -0.00
- Stochastic Oscillator
- SXTP 53.88
- VTAK 33.14
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.